Cardiff Oncology
CRDF
26 hedge funds and large institutions have $915K invested in Cardiff Oncology in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 8 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
0.28% less ownership
Funds ownership: 1.53% → 1.25% (-0.28%)
21% less funds holding
Funds holding: 33 → 26 (-7)
31% less capital invested
Capital invested by funds: $1.32M → $915K (-$408K)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$92.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84.4K |
| 3 |
Renaissance Technologies
New York
|
+$68.5K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$30.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$16.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$125K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$59.6K |
| 3 |
Two Sigma Investments
New York
|
-$30K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$15K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | +$155 | +34 | +54% |
|
27
Wells Fargo
San Francisco,
California
| – | +$196 | +43 | +100% |
|
CRDF Hedge Fund Activity: Q4 2018 in Review
26 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2018, worth a combined $915K — down 31% from $1.32M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CRDF and 1 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, adding an estimated $92.9K. The largest seller was Sabby Management, exiting entirely with an estimated $125K sold.
- 26 institutional investors held Cardiff Oncology (CRDF) as of Q4 2018, down from 33 in Q3 2018.
- Funds reported $915K of Cardiff Oncology stock for Q4 2018, down 31% quarter-over-quarter.
- 1 fund opened new Cardiff Oncology positions in Q4 2018 and 8 closed out, a net change of -7 holders.
- The largest Cardiff Oncology buyer in Q4 2018 was Susquehanna International Group, an estimated $92.9K added.
- The largest Cardiff Oncology seller in Q4 2018 was Sabby Management, an estimated $125K sold.
Based on aggregated 13F filings for Q4 2018.